Healthcare News

PRESS RELEASE CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor LONDON – 18 August 2026 -- CHARM Therapeutics...

Peak Physio has opened Arcane Physio, a clinical education and reference platform, to external subscribers, targeting physiotherapists.

Company announcement no. 31 - 2618 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Dr. Charuworn’s extensive immunology drug development experience will help accelerate the clinical development of Coultreon’s first-in-class SIK3 inhibitor COL-5671 Leuven, Belgium. August 18, 2026....

Interim financial results, 9M 2025/261 October 2025 - 30 June 2026 Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1 in constant currencies. Strong quarter in both Chronic Care ex....

9M 2025/26Delårsrapport, 9M 2025/261. oktober 2025 – 30. juni 2026 Coloplast leverede i Q3 en organisk vækst på 6% og en EBIT-vækst1 på 5% i faste valutakurser. Stærkt kvartal i både Chronic Care ex....

Total revenue increases by 14% to CHF 119 millionOperating profit increases by 32% to CHF 32 million and net profit by 77% to CHF 28 millionFosmanogepix phase 3 program on track for data readout and...

14 % Wachstum des Gesamtumsatzes auf CHF 119 Mio.32 % Steigerung des Betriebsgewinns auf CHF 32 Mio. und 77 % Steigerung des Gewinns auf CHF 28 Mio.Phase-3-Programm mit Fosmanogepix auf Kurs für die...

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company...

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company’s Board of...